Biotechnology & Healthcare
Abbott (NYSE: ABT) received FDA approval for its Coronary Intravascular Lithotripsy (IVL) System to treat severe coronary calcification ahead of stenting. The TECTONIC trial, enrolling up to 335 patients at 47 U.S. sites, marks a key advancement in interventional cardiology, as detailed in the trial announcement.
CEL‐SCI (NYSE: CVM) reported new Phase 3 data showing that treatment with Multikine led to up to 95.1% improvement in quality of life for complete responders among head and neck cancer patients, according to the research release.
Tenon Medical (NASDAQ: TNON) announced FDA clearance for an expanded indication of its Catamaran® SI Joint Fusion System, paving the way for its use as either a standalone procedure or an adjunct in spinal fusion. Further data from the ongoing MAINSAIL clinical trial are anticipated, as explained in the regulatory update.
Maravai LifeSciences (NASDAQ: MRVI) faces a class action lawsuit after delaying its earnings release and annual report on February 25, 2025, triggering a 21.7% stock price decline. The suit, citing misleading financial disclosures between August 7, 2024 and February 24, 2025, sets a key court deadline of May 5, 2025, as outlined in the news alert.
Quince Therapeutics (NASDAQ: QNCX) provided an update on its Phase 3 NEAT clinical trial for Ataxia‐Telangiectasia along with a cash position of $40.8 million and an FDA Fast Track designation, as detailed in the company update.
Artiva Biotherapeutics (NASDAQ: ARTV) reported its full year 2024 financial results, ending with $185.4 million in cash and investments and a net loss of $65.4 million, while highlighting upcoming clinical data from its AlloNK® autoimmune program as described in the earnings release.
Neurogene (NASDAQ: NGNE) released its Q4 and full year 2024 financial results, underscoring progress in its NGN-401 Phase 1/2 trial for Rett syndrome with encouraging interim efficacy data at the 1E15 vg dose. The company reported a cash position of $312.4 million and a net loss of $75.1 million for 2024, with further updates expected in H2 2025, as noted in the financial update.
Bolt Biotherapeutics (NASDAQ: BOLT) reported its Q4 and full-year 2024 results, highlighting its cancer immunotherapy pipeline. With a robust cash position of $70.2 million set to fund operations through mid‑2026, the company is advancing its BDC-4182 program for gastric cancer and has completed enrollment for its BDC-3042 Phase 1 trial, as detailed in the company update.
Actinium Pharmaceuticals (NYSE: ATNM) secured a supply agreement with Eckert & Ziegler for the critical radioisotope Ac-225, which will support the development of its lead product Actimab-A for acute myeloid leukemia and other myeloid conditions. The agreement paves the way for pivotal Phase 2/3 trials and expanded evaluations in solid tumors, as outlined in the supply update.
Technology, Industrial & Energy
CrowdStrike (CRWD) enhanced its Falcon Exposure Management platform with an AI-powered Network Vulnerability Assessment for real-time detection and remediation of network flaws, streamlining legacy security systems as described in the initiative update.
Standard Lithium (SLI) reported strong six‑month fiscal results bolstered by a $225 million grant from the U.S. Department of Energy and breakthrough lithium recovery efficiencies at its South West Arkansas project, as noted in the financial update.
Rithm Capital (RITM) closed the largest-ever mortgage servicing rights debt issuance by securing $878 million in a single-tranche securitization deal, a milestone that underscores its strength in structured finance, as explained in the official announcement.
Enerpac Tool Group (NYSE: EPAC) reported strong Q2 fiscal 2025 results with net sales of $146 million—a 5.1% year-over-year increase—and maintained its guidance for the year. The company also returned $10 million to shareholders through share repurchases, as detailed in the fiscal update.
Faraday Future (NASDAQ: FFAI) secured a new $41 million funding commitment via convertible notes and warrants, accelerating development of its FX brand and AI enhancements for autonomous driving. This latest financing round bolsters total fundraising to over $100 million since September 2024, as noted in the funding update.
Satellogic (NASDAQ: SATL) reported its 2024 financial results with a 28% revenue increase to $12.9 million, improved cost metrics, and a strategic redomicile to the U.S. A $10 million private placement and a $50 million ATM program further support its commercial milestones, as outlined in the business update.
Corporate & Financial Updates
Norwegian Cruise Line (NCL) launched its newest vessel, Norwegian Aqua, featuring innovations like the Aqua Slidecoaster and a state-of-the-art Glow Court digital sports complex—marking a milestone in fleet expansion, as described in the voyage update.
SKYX Platforms Corp. (NASDAQ: SKYX) reported an impressive 48% revenue growth in 2024, with revenues rising from $58.8 million in 2023 to $86.3 million, driven by strong quarterly performances and a strategic preferred stock investment, as explained in the company update.
Western Union (WU) formed a strategic partnership with HCLTech to transition to an AI-led operating model and is establishing a new technology center in Hyderabad, India, a move that underscores its commitment to digital transformation, as outlined in the partnership update.
Endeavor Group Holdings confirmed its acquisition by Silver Lake, with shareholders receiving $27.50 per share—a 55% premium that valued the company at $25 billion—as reported in the acquisition announcement.
GoHealth Inc. (NASDAQ: GOCO) posted a robust Q4 2024 performance with net revenues climbing 41% YoY to $389.1 million and turning around to a net income of $58.0 million after last year’s loss, as recounted in the coverage update.
Parsons (NYSE: PSN) expanded its stock repurchase authorization to $250 million following strong operating results and cash flow performance. CEO Carey Smith indicated that this move supports share repurchases while also enabling continued investments in growth opportunities, as detailed in the announcement.
Prairie Operating Co. (NASDAQ: PROP) announced a registered direct offering of 150,000 shares of new Series F Convertible Preferred Stock with a 12% annual dividend rate to help fund the acquisition of oil and gas assets from Bayswater Exploration and Production, according to the offering update.
KB Home (KBH) reported its Q1 2025 results with revenues of $1.39 billion, a 5% decline YoY, and revised fiscal guidance for 2025 amid muted spring demand. The company also repurchased shares worth $50.0 million, as described in the quarterly results.
American Electric Power (AEP) announced a registered underwritten offering of $2 billion of common stock with a forward sale component, with an option to purchase up to an additional $300 million in shares. The proceeds will support general corporate purposes including capital contributions, acquisitions, and debt repayment, as outlined in the offering details.
Crown Castle (NYSE: CCI) announced an immediate leadership transition with Daniel Schlanger stepping in as interim CEO following Steven Moskowitz's termination. The Board is now searching for a permanent CEO as Schlanger transitions later to Chief Transformation Officer, as explained in the CEO transition update.
